8-K Announcements
6Material company update
Apr 21, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Jan 30, 2026·SEC
Beta Bionics, Inc.(BBNX)Earnings, Financials & Key Ratios
BBNX•NASDAQ
Price updated Jun 19, 2026
AboutBeta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.Show more
- Revenue$100M+53.9%
- EBITDA-$73M-66.0%
- Net Income-$73M-33.7%
- EPS (Diluted)-1.81+79.0%
- Gross Margin55.4%+0.5%
- EBITDA Margin-73.02%-7.8%
- Operating Margin-71.5%-2.9%
- Net Margin-73.02%+13.2%
- ROE-40.26%+50.5%
BBNX Key Insights
Beta Bionics, Inc. (BBNX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BBNX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BBNX Price & Volume
Beta Bionics, Inc. (BBNX) stock price & volume — 10-year historical chart
Loading chart...
BBNX Growth Metrics
Beta Bionics, Inc. (BBNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years724.29%
TTM62.79%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.64%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM54.38%
Return on Capital
10 Years-94.31%
5 Years-94.31%
3 Years-43.4%
Last Year-33.63%
BBNX Recent Earnings
Beta Bionics, Inc. (BBNX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/9 qtrs (67%)●Beat Revenue 4/9 qtrs (67%)
Q2 2026Latest
Apr 21, 2026Metric
Actual
Est
EPS
$0.49+7.5%
$0.53
Rev
$28M+2.5%
$27M
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$0.30+28.6%
$0.42
Rev
$32M+5.7%
$30M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$0.33+26.7%
$0.45
Rev
$27M-5.7%
$29M
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$0.39+23.5%
$0.51
Rev
$23M+6.1%
$22M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 21, 2026 | $0.49vs $0.53+7.5% | $28Mvs $27M+2.5% |
| Q1 2026 | Feb 17, 2026 | $0.30vs $0.42+28.6% | $32Mvs $30M+5.7% |
| Q4 2025 | Oct 28, 2025 | $0.33vs $0.45+26.7% | $27Mvs $29M-5.7% |
| Q3 2025 | Jul 29, 2025 | $0.39vs $0.51+23.5% | $23Mvs $22M+6.1% |
Based on last 9 quarters of dataView full earnings history →
BBNX Peer Comparison
Beta Bionics, Inc. (BBNX) competitors in Medical Devices and Procedure Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TNDM | 1.05B | 15.30 | -5.03 | 7.93% | -9.2% | -68.29% | 2.86 | |
 PODD | 10.23B | 145.76 | 41.89 | 30.73% | 10.44% | 21.38% | 0.69 | |
 DXCM | 27.96B | 72.47 | 34.67 | 15.6% | 19.31% | 33.83% | 0.51 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 RCEL | 99.62M | 4.01 | -2.30 | 11.45% | -62.67% | |||
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 |
Compare BBNX vs Peers
Beta Bionics, Inc. (BBNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BBNX Income Statement
Beta Bionics, Inc. (BBNX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Sales/Revenue | 179K | 11.99M | 65.12M | 100.25M | 110.24M |
Revenue Growth % | - | 6601.12% | 442.93% | 53.94% | 62.79% |
Cost of Goods Sold | 0 | 5.69M | 29.24M | 44.71M | 47.23M |
COGS % of Revenue | - | 47.41% | 44.89% | 44.6% | - |
Gross Profit | 179K▲ 0% | 6.31M▲ 3424.0% | 35.89M▲ 468.9% | 55.54M▲ 54.8% | 63M▲ 0% |
Gross Margin % | 100% | 52.59% | 55.11% | 55.4% | 57.15% |
Gross Profit Growth % | - | 3424.02% | 468.93% | 54.75% | - |
Operating Expenses | 66.02M | 42.16M | 81.14M | 127.22M | 140.31M |
OpEx % of Revenue | 36884.36% | 351.46% | 124.59% | 126.9% | - |
Selling, General & Admin | 33.49M | 24.21M | 54.95M | 92.43M | 102.76M |
SG&A % of Revenue | 18712.29% | 201.88% | 84.39% | 92.2% | - |
Research & Development | 31.43M | 17.94M | 26.18M | 34.79M | 37.55M |
R&D % of Revenue | 17557.54% | 149.59% | 40.21% | 34.7% | - |
Other Operating Expenses | 1.1M | 0 | 0 | 0 | 0 |
Operating Income | -65.84M▲ 0% | -35.85M▲ 45.6% | -45.25M▼ 26.2% | -71.68M▼ 58.4% | -77.31M▲ 0% |
Operating Margin % | -36784.36% | -298.87% | -69.48% | -71.5% | -70.13% |
Operating Income Growth % | - | 45.55% | -26.22% | -58.41% | - |
EBITDA | -64.5M | -34.62M | -44.1M | -73.2M | -77.91M |
EBITDA Margin % | -36032.96% | -288.65% | -67.72% | -73.02% | -70.68% |
EBITDA Growth % | - | 46.32% | -27.37% | -65.98% | -55.5% |
D&A (Non-Cash Add-back) | 1.34M | 1.23M | 1.15M | 0 | -604K |
EBIT | -64.74M | -35.85M | -45.25M | -73.2M | -68.81M |
Net Interest Income | 182K | 1.78M | 3.91M | 10.93M | 10.87M |
Interest Income | 196K | 1.78M | 3.91M | 10.93M | 10.87M |
Interest Expense | 14K | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.09M | -8.25M | -9.51M | -1.52M | 10.87M |
Pretax Income | -64.75M▲ 0% | -44.1M▲ 31.9% | -54.76M▼ 24.2% | -73.2M▼ 33.7% | -66.44M▲ 0% |
Pretax Margin % | -36173.74% | -367.64% | -84.08% | -73.02% | -60.27% |
Income Tax | 0 | 0 | 0 | 1K | 1K |
Effective Tax Rate % | 0% | 0% | 0% | -0% | -0% |
Net Income | -64.75M▲ 0% | -44.1M▲ 31.9% | -54.76M▼ 24.2% | -73.2M▼ 33.7% | -66.44M▲ 0% |
Net Margin % | -36173.74% | -367.64% | -84.08% | -73.02% | -60.27% |
Net Income Growth % | - | 31.89% | -24.17% | -33.68% | 3.64% |
Net Income (Continuing) | -64.75M | -44.1M | -54.76M | -73.2M | -66.44M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -12.96▲ 0% | -8.31▲ 35.9% | -8.60▼ 3.5% | -1.81▲ 79.0% | -1.50▲ 0% |
EPS Growth % | - | 35.88% | -3.49% | 78.95% | 54.38% |
EPS (Basic) | -12.96 | -8.31 | -8.60 | -1.81 | - |
Diluted Shares Outstanding | 5M | 5.3M | 6.37M | 40.53M | 44.44M |
Basic Shares Outstanding | 5M | 5.3M | 6.37M | 40.53M | 44.44M |
Dividend Payout Ratio | - | - | - | - | - |
BBNX Balance Sheet
Beta Bionics, Inc. (BBNX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Total Current Assets | 28.47M | 103.62M | 132.92M | 267.9M | 247.99M |
Cash & Short-Term Investments | 27.68M | 96.75M | 103.58M | 219.22M | 199.52M |
Cash Only | 27.68M | 26.57M | 30.43M | 31.68M | 30.21M |
Short-Term Investments | 0 | 70.18M | 73.14M | 187.55M | 169.31M |
Accounts Receivable | 0 | 4.45M | 12M | 17.12M | 17.89M |
Days Sales Outstanding | - | 135.35 | 67.23 | 62.32 | 50.21 |
Inventory | 0 | 1.25M | 13.32M | 21.72M | 23.73M |
Days Inventory Outstanding | - | 79.91 | 166.29 | 177.32 | 160.62 |
Other Current Assets | 250K | 275K | 1.05M | 9.84M | 6.85M |
Total Non-Current Assets | 7.06M | 6.42M | 16.72M | 60.84M | 56.43M |
Property, Plant & Equipment | 6.87M | 6.2M | 11.42M | 15.23M | 16.39M |
Fixed Asset Turnover | 0.03x | 1.94x | 5.70x | 6.58x | 7.53x |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 45.43M | 161.77M |
Other Non-Current Assets | 193K | 221K | 5.3M | 180K | 181K |
Total Assets | 35.53M▲ 0% | 110.04M▲ 209.7% | 149.65M▲ 36.0% | 328.74M▲ 119.7% | 304.42M▲ 0% |
Asset Turnover | 0.01x | 0.11x | 0.44x | 0.30x | 0.34x |
Asset Growth % | - | 209.74% | 35.99% | 119.68% | 350.21% |
Total Current Liabilities | 8.87M | 10.61M | 21.15M | 30.92M | 23.19M |
Accounts Payable | 430K | 1.17M | 2.85M | 5M | 2.32M |
Days Payables Outstanding | - | 74.84 | 35.61 | 40.8 | 29.37 |
Short-Term Debt | 0 | 0 | 0 | 0 | 1.84M |
Deferred Revenue (Current) | 0 | 0 | 939K | 1.56M | 5.75M |
Other Current Liabilities | 1.32M | 1.14M | 10.94M | 22.43M | 17.33M |
Current Ratio | 3.21x | 9.77x | 6.29x | 8.66x | 10.69x |
Quick Ratio | 3.21x | 9.65x | 5.66x | 7.96x | 9.67x |
Cash Conversion Cycle | - | 140.42 | 197.92 | 198.84 | 181.46 |
Total Non-Current Liabilities | 13.65M | 40.83M | 52.48M | 10.21M | 9.98M |
Long-Term Debt | 0 | 0 | 0 | 5.37M | 5.07M |
Capital Lease Obligations | 3.16M | 3M | 5.73M | 5.37M | 21.31M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10.5M | 37.83M | 44.9M | 1.55M | 1.56M |
Total Liabilities | 22.53M | 51.43M | 73.63M | 41.13M | 33.17M |
Total Debt | 4.13M | 4.22M | 7.25M | 12.67M | 6.91M |
Net Debt | -23.54M | -22.34M | -23.18M | -19.01M | -23.29M |
Debt / Equity | 0.32x | 0.07x | 0.10x | 0.04x | 0.03x |
Debt / EBITDA | - | - | - | - | -0.09x |
Net Debt / EBITDA | - | - | - | - | 0.30x |
Interest Coverage | -4624.57x | - | - | - | - |
Total Equity | 13M▲ 0% | 58.61M▲ 350.8% | 76.01M▲ 29.7% | 287.61M▲ 278.4% | 271.25M▲ 0% |
Equity Growth % | - | 350.83% | 29.7% | 278.37% | 1061.68% |
Book Value per Share | 2.60 | 11.05 | 11.94 | 7.10 | 6.10 |
Total Shareholders' Equity | 13M | 58.61M | 76.01M | 287.61M | 271.25M |
Common Stock | 1K | 1K | 1K | 4K | 5K |
Retained Earnings | -185.56M | -229.66M | -296.74M | -369.94M | -391.83M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 137K | 65K | 403K | -96K |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
BBNX Cash Flow Statement
Beta Bionics, Inc. (BBNX) cash flow — operating, investing & free cash flow history
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -60.21M | -32.45M | -48.27M | 0 | -46.16M |
Operating CF Margin % | -33635.75% | -270.49% | -74.12% | - | - |
Operating CF Growth % | - | 46.11% | -48.78% | 100% | 89.89% |
Net Income | -64.75M | -44.1M | -54.76M | -73.2M | -66.44M |
Depreciation & Amortization | 2.09M | 2.09M | 2.28M | 0 | 2.01M |
Stock-Based Compensation | 6.1M | 5.66M | 6.38M | 16.38M | 18.99M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -854K | 10.27M | 9.96M | 56.82M | 8.69M |
Working Capital Changes | -2.79M | -6.36M | -12.15M | 0 | -9.4M |
Change in Receivables | 0 | -4.49M | -7.62M | 0 | -1.14M |
Change in Inventory | 0 | -1.19M | -11.44M | 0 | -6.86M |
Change in Payables | -77K | 0 | 1.51M | 0 | -1.67M |
Cash from Investing | -769K | -69.69M | -3.48M | 0 | 37.5M |
Capital Expenditures | -772K | -402K | -3.4M | 0 | -4.44M |
CapEx % of Revenue | 431.28% | 3.35% | 5.21% | - | 4.03% |
Acquisitions | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - |
Other Investing | 3K | -69.29M | 50K | 0 | 0 |
Cash from Financing | 56.78M | 101.03M | 55.62M | 0 | 3.32M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 56.39M | 0 | 55.62M | 0 | 3.32M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 |
Other Financing | 389K | 101.03M | 0 | 0 | 0 |
Net Change in Cash | -4.2M▲ 0% | -1.11M▲ 73.6% | 3.87M▲ 448.6% | -30.53M▼ 889.8% | -43.92M▲ 0% |
Free Cash Flow | -60.98M▲ 0% | -32.85M▲ 46.1% | -51.67M▼ 57.3% | 0▲ 100.0% | -50.59M▲ 0% |
FCF Margin % | -34067.04% | -273.84% | -79.34% | - | -45.89% |
FCF Growth % | - | 46.13% | -57.3% | 100% | 14.59% |
FCF per Share | -12.20 | -6.19 | -8.12 | - | -1.14 |
FCF Conversion (FCF/Net Income) | 0.93x | 0.74x | 0.88x | - | 0.76x |
Interest Paid | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 |
BBNX Key Ratios
Beta Bionics, Inc. (BBNX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
Return on Equity (ROE) | -123.17% | -81.35% | -40.26% | -23% |
Return on Invested Capital (ROIC) | -209.05% | -76.18% | -33.45% | -22.12% |
Gross Margin | 52.59% | 55.11% | 55.4% | 57.15% |
Net Margin | -367.64% | -84.08% | -73.02% | -60.27% |
Debt / Equity | 0.07x | 0.10x | 0.04x | 0.03x |
FCF Conversion | 0.74x | 0.88x | - | 0.76x |
Revenue Growth | 6601.12% | 442.93% | 53.94% | 62.79% |
Related:BBNX Dividend History·BBNX Revenue History·BBNX Price History·BBNX P/E History·BBNX Financial Ratios·BBNX Institutional Holders
BBNX SEC Filings & Documents
Beta Bionics, Inc. (BBNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BBNX Frequently Asked Questions
Beta Bionics, Inc. (BBNX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Beta Bionics, Inc. (BBNX) reported $110.2M in revenue for fiscal year 2025. This represents a 61485% increase from $0.2M in 2022.
Beta Bionics, Inc. (BBNX) grew revenue by 53.9% over the past year. This is strong growth.
Beta Bionics, Inc. (BBNX) reported a net loss of $66.4M for fiscal year 2025.
Dividend & Returns
Beta Bionics, Inc. (BBNX) has a return on equity (ROE) of -40.3%. Negative ROE indicates the company is unprofitable.
Beta Bionics, Inc. (BBNX) had negative free cash flow of $50.6M in fiscal year 2025, likely due to heavy capital investments.